Invention Grant
US09447419B2 RNAi-mediated inhibition of tumor necrosis factor α-related conditions
有权
RNAi介导的抑制肿瘤坏死因子α相关病症
- Patent Title: RNAi-mediated inhibition of tumor necrosis factor α-related conditions
- Patent Title (中): RNAi介导的抑制肿瘤坏死因子α相关病症
-
Application No.: US14244623Application Date: 2014-04-03
-
Publication No.: US09447419B2Publication Date: 2016-09-20
- Inventor: John M. Yanni , Jon E. Chatterton , Diane Michelle Senchyna , Daniel A. Gamache , Steven T. Miller
- Applicant: Arrowhead Research Corporation
- Applicant Address: US CA Pasadena
- Assignee: Arrowhead Pharmaceuticals, Inc.
- Current Assignee: Arrowhead Pharmaceuticals, Inc.
- Current Assignee Address: US CA Pasadena
- Main IPC: C12N15/113
- IPC: C12N15/113 ; A61K31/7088 ; A61K31/713
Abstract:
RNA interference is provided for inhibition of tumor necrosis factor α (TNFα) by silencing TNFα cell surface receptor TNF receptor-1 (TNFR1) mRNA expression, or by silencing TNFα converting enzyme (TACE/ADAM17) mRNA expression. Silencing such TNFα targets, in particular, is useful for treating patients having a TNFα-related condition or at risk of developing a TNFα-related condition such as the ocular conditions dry eye, allergic conjunctivitis, or ocular inflammation, or such as dermatitis, rhinitis, or asthma, for example.
Public/Granted literature
- US20140357694A1 RNAi-MEDIATED INHIBITION OF TUMOR NECROSIS FACTOR ALPHA-RELATED CONDITIONS Public/Granted day:2014-12-04
Information query
IPC分类:
